Table I.
Characteristics of patients who underwent an allogeneic transplant after a failed autologous transplant for DLBCL from 2000–2012 reported to the CIBMTR. (Italicized text indicates variables available in CRF-level data patients).
| Number of patients | 503 |
| Number of CRF-level data patients | 155 |
| Number of centres | 133 |
| Median age at transplant, years (range) | 52 (19–72) |
| Male gender | 305 (61) |
| Race | |
| Caucasian/White | 444 (88) |
| Black | 17 (3) |
| Others1 | 33 (7) |
| Missing | 9 (2) |
| Karnofsky Performance Score | |
| 80–100% | 393 (78) |
| <80% | 52 (10) |
| Missing | 58 (12) |
| Stage III/IV at Diagnosis | 83 (54) |
| Remission status at HCT | |
| Complete remission | 175 (35) |
| Partial remission | 197 (39) |
| Chemorefractory | 106 (21) |
| Untreated | 12 (2) |
| Unknown | 13 (3) |
| Rituximab prior to HCT | 112 (72) |
| Radiation therapy prior to HCT | 98 (63) |
| Lines of therapy prior to alloHCT | |
| Median (range) | 4 (1–7) |
| History of transformation from indolent histology | 25 (16) |
| Elevated lactate dehydrogenase at HCT | 52 (34) |
| Active extranodal disease at HCT | 49 (32) |
| Bone marrow involvement at HCT | |
| No bone marrow involvement | 141 (91) |
| Bone marrow involvement | 7 (5) |
| Missing | 7 (5) |
| Bulky Disease (>5 cm) at HCT | 15 (10) |
| Conditioning regimen intensity | |
| Myeloablative | 127 (25) |
| Reduced intensity conditioning | 376 (75) |
| TBI in conditioning regimens | |
| Myeloablative doses of TBI | 41 (8) |
| Graft type | |
| Bone marrow | 47 (9) |
| Peripheral Blood | 456 (91) |
| Type of donor | |
| HLA-identical sibling | 253 (50) |
| Unrelated well-matched | 118 (23) |
| Unrelated partially matched | 132 (26) |
| Donor-Recipient CMV Status | |
| −/+ | 102 (20) |
| Other | 226 (45) |
| Missing | 175 (35) |
| GVHD Prophylaxis | |
| CNI + MMF +- others | 180 (36) |
| CNI + MTX +-others (except MMF) | 219 (43) |
| CNI + others (except MTX, MMF) | 64 (13) |
| Other GVHD prophylaxis2 | 7 (1) |
| Missing GVHD prophylaxis | 33 (7) |
| Antithymocyte globulin in conditioning | 110 (22) |
| Alemtuzumab in conditioning | 7 (1) |
| Year of Transplant | |
| 2000–2003 | 111 (22) |
| 2004–2007 | 154 (31) |
| 2008–2012 | 238 (47) |
| Time from autoHCT to alloHCT | |
| Median (range) | 15 (1–198) |
| ≤12 months | 201 (40) |
| >12 months | 302 (60) |
| Median follow-up of survivors (range), months | 55 (1–149) |
HCT=haematopoietic cell transplantation; alloHCT=allogeneic haematopoietic cell transplantation; autoHCT= autologous haematopoietic cell transplantation; TBI=total body irrdation; CMV=Cytomegalovirus; GVHD=graft-versus-host disease; CNI=calcineurin inhibitor; MMF=mycophenolate mofetil; MTX=methotrexate
1
Asian (n=25), Native American (n=1), Pacific Islander (n=1), other (n=6)
2
MMF/Campath (n=1), MMF/Sirolimus (n=1), MTX(n=3), MMF/MTX(n=1), MMF/MTX/Sirolimus (n=1)